Editorial: does anti-TNF 'treatment persistence' always equate to 'effective treatment'? Only objective disease assessments can answer the question. Authors' reply

Aliment Pharmacol Ther. 2021 Sep;54(5):720-721. doi: 10.1111/apt.16535.

Authors

Andreas Blesl¹, Christoph Högenauer^{1

2}, Andrea Borenich³, Andrea Berghold³, Heimo Wenzl¹, Wolfgang Petritsch¹

Affiliations

¹ Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
² Biotechmed, Graz, Austria.
³ Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.

PMID: 34379834
DOI: 10.1111/apt.16535

No abstract available

Publication types

Editorial
Comment

MeSH terms

Humans
Inflammatory Bowel Diseases*
Treatment Outcome
Tumor Necrosis Factor Inhibitors*
Tumor Necrosis Factor-alpha

Substances

Tumor Necrosis Factor Inhibitors
Tumor Necrosis Factor-alpha